Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: BUY (auto-tracking)
2.26% $4.98
America/New_York / 26 apr 2024 @ 10:07
FUNDAMENTALS | |
---|---|
MarketCap: | 720.20 mill |
EPS: | -0.540 |
P/E: | -9.22 |
Earnings Date: | May 02, 2024 |
SharesOutstanding: | 144.62 mill |
Avg Daily Volume: | 2.09 mill |
RATING 2024-04-25 |
---|
B+ |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Buy | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -9.22 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.57x |
Company: PE -9.22 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 4.76 - 5.22 ( +/- 4.53%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-06 | Greenleaf Peter | Sell | 126 981 | Common Stock |
2024-03-06 | Miller Joseph M | Sell | 34 811 | Common Stock |
2024-03-06 | Donley Matthew Maxwell | Sell | 40 665 | Common Stock |
2024-03-06 | Habig Scott Michael | Sell | 17 777 | Common Stock |
2024-03-06 | Robertson Stephen P. | Sell | 57 745 | Common Stock |
INSIDER POWER |
---|
72.32 |
Last 95 transactions |
Buy: 5 896 445 | Sell: 560 044 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $4.98 (2.26% ) |
Volume | 0.135 mill |
Avg. Vol. | 2.09 mill |
% of Avg. Vol | 6.43 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:34 | sell | $7.90 | N/A | Active |
---|
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.